Rabies mAb CBB 1 Combination Vaccine in Healthy People With Antibody Neutralization Activity and Safety Phase Clinical Trials

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2025

Conditions
Rabies Virus Infection
Interventions
DRUG

Natural full human monoclonal antibody CBB 1 injection 50.0µg/kg

Active ingredient: natural full human monoclonal antibody CBB 1 containing 0.5 mg / ml per dose (2.5ml) Ingredients: 25 mM citrate buffer, 125 mM sodium chloride, 0.02% (w / v) polysorbate 20 and water for injection

DRUG

Natural full human monoclonal antibody CBB 1 injection 100.0µg/kg

Active ingredient: natural full human monoclonal antibody CBB 1 containing 0.5 mg / ml per dose (2.5ml) Ingredients: 25 mM citrate buffer, 125 mM sodium chloride, 0.02% (w / v) polysorbate 20 and water for injection

DRUG

Rabies Human Immunoglobulin (HRIG)

Active ingredient: Rabid human immunoglobulin

BIOLOGICAL

Lyophilized rabies vaccine for human use (Vero cells)

Active ingredient: inactivated rabies virus fixed poison

Trial Locations (1)

650000

The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine, Kunming

All Listed Sponsors
collaborator

The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine

UNKNOWN

collaborator

Anning City First People's Hospital

UNKNOWN

collaborator

Yunnan Central Hospital

UNKNOWN

collaborator

Beijing Contreke Statistical Technology Co., LTD

UNKNOWN

collaborator

Military Science Zhengyuan (Beijing) Pharmaceutical Research Co., LTD

UNKNOWN

lead

Changchun BCHT Biotechnology Co.

INDUSTRY

NCT06548139 - Rabies mAb CBB 1 Combination Vaccine in Healthy People With Antibody Neutralization Activity and Safety Phase Clinical Trials | Biotech Hunter | Biotech Hunter